Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Head & Neck 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Sarcoma 4Melanoma 4Breast Neoplasms 3Urinary Bladder Neoplasms 2Osteosarcoma 2Gliosarcoma 2Glioblastoma 2Carcinoma, Merkel Cell 2Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Chondrosarcoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Bone Neoplasms 1Adenocarcinoma 1

Interventions

Filgrastim 10Ifosfamide 6Carboplatin 5Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Doxorubicin 4Cyclophosphamide 4pembrolizumab 3Thiotepa 3Temozolomide 3Etoposide 3Busulfan 3sargramostim 2ixabepilone 2fludarabine phosphate 2etoposide phosphate 2belinostat 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Paclitaxel 2Mycophenolic Acid 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Bortezomib 2Antilymphocyte Serum 2Amifostine 2tremelimumab 1seribantumab 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × poly ICLC × Sarcoma × Clear all
NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡